Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

439 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of N-2,4-pyrimidine-N-phenyl-N'-alkyl ureas as orally active inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 2.
Maier JA, Brugel TA, Clark MP, Sabat M, Golebiowski A, Bookland RG, Laufersweiler MJ, Laughlin SK, Vanrens JC, De B, Hsieh LC, Brown KK, Juergens K, Walter RL, Janusz MJ. Maier JA, et al. Among authors: de b. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3514-8. doi: 10.1016/j.bmcl.2006.03.096. Epub 2006 Apr 24. Bioorg Med Chem Lett. 2006. PMID: 16632350
Development of N-2,4-pyrimidine-N-phenyl-N'-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 1.
Brugel TA, Maier JA, Clark MP, Sabat M, Golebiowski A, Bookland RG, Laufersweiler MJ, Laughlin SK, Vanrens JC, De B, Hsieh LC, Mekel MJ, Janusz MJ. Brugel TA, et al. Among authors: de b. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3510-3. doi: 10.1016/j.bmcl.2006.03.095. Epub 2006 May 2. Bioorg Med Chem Lett. 2006. PMID: 16632356
Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3).
Clark MP, George KM, Bookland RG, Chen J, Laughlin SK, Thakur KD, Lee W, Davis JR, Cabrera EJ, Brugel TA, VanRens JC, Laufersweiler MJ, Maier JA, Sabat MP, Golebiowski A, Easwaran V, Webster ME, De B, Zhang G. Clark MP, et al. Among authors: de b. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1250-3. doi: 10.1016/j.bmcl.2006.12.018. Epub 2006 Dec 9. Bioorg Med Chem Lett. 2007. PMID: 17189692
Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production.
Clark MP, Laughlin SK, Laufersweiler MJ, Bookland RG, Brugel TA, Golebiowski A, Sabat MP, Townes JA, VanRens JC, Djung JF, Natchus MG, De B, Hsieh LC, Xu SC, Walter RL, Mekel MJ, Heitmeyer SA, Brown KK, Juergens K, Taiwo YO, Janusz MJ. Clark MP, et al. Among authors: de b. J Med Chem. 2004 May 20;47(11):2724-7. doi: 10.1021/jm049968m. J Med Chem. 2004. PMID: 15139749
The development of novel inhibitors of tumor necrosis factor-alpha (TNF-alpha) production based on substituted [5,5]-bicyclic pyrazolones.
Laufersweiler MJ, Brugel TA, Clark MP, Golebiowski A, Bookland RG, Laughlin SK, Sabat MP, Townes JA, VanRens JC, De B, Hsieh LC, Heitmeyer SA, Juergens K, Brown KK, Mekel MJ, Walter RL, Janusz MJ. Laufersweiler MJ, et al. Among authors: de b. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4267-72. doi: 10.1016/j.bmcl.2004.06.001. Bioorg Med Chem Lett. 2004. PMID: 15261284
439 results